<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0345">
 <label>69</label>
 <element-citation publication-type="journal" id="rf0340">
  <person-group person-group-type="author">
   <name>
    <surname>Curtis</surname>
    <given-names>J.R.</given-names>
   </name>
   <name>
    <surname>Xie</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Yun</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Bernatsky</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Winthrop</surname>
    <given-names>K.L.</given-names>
   </name>
  </person-group>
  <article-title>Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis</article-title>
  <source>Ann Rheum Dis</source>
  <volume>75</volume>
  <year>2016</year>
  <fpage>1843</fpage>
  <lpage>1847</lpage>
  <pub-id pub-id-type="doi">10.1136/annrheumdis-2016-209131</pub-id>
  <pub-id pub-id-type="pmid">27113415</pub-id>
 </element-citation>
</ref>
